small molecule

BARHEMSYS

AMISULPRIDE

Loss of exclusivityFebruary 2038latest FDA-listed patent expiry
CompanyACACIA PHARMA LTD

Drug detail

Brand nameBARHEMSYS
Active ingredientAMISULPRIDE
Strength10MG/4ML (2.5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2020
Marketing statusRX

Listed patents

PatentExpiresType
12329740February 2038use U-3467
11357753February 2038use U-2754
12005042February 2038use U-1744
9084765February 2034use U-3467
10525033March 2031product
9889118March 2031use U-1744
9545426March 2031use U-1744
12194022March 2031use U-3467

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BARHEMSYS patent cliff — loss of exclusivity February 2038 | CliffBio